Morgan Stanley Lantern Pharma Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Morgan Stanley holds 600 shares of LTRN stock, worth $2,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares

600

Previous 715 16.08%

Holding current value

$2,268

Previous $6,000 66.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.91 - $9.51 $449 - $1,093	-115 Reduced 16.08%	600 $2,000
Q1 2024 Aug 16, 2024	BUY	$3.73 - $10.65 $428 - $1,224	115 Added 19.17%	715 $6,000
Q1 2024 May 15, 2024	BUY	$3.73 - $10.65 $428 - $1,224	115 Added 19.17%	715 $6,000
Q4 2023 Feb 13, 2024	BUY	$2.48 - $4.39 $1,488 - $2,634	600 New	600 $2,000
Q4 2022 Feb 14, 2023	SELL	$4.19 - $6.04 $20 - $30	-5 Reduced 1.7%	289 $1,000
Q3 2022 Nov 14, 2022	SELL	$4.59 - $6.5 $5,049 - $7,150	-1,100 Reduced 78.91%	294 $1,000
Q2 2022 Oct 27, 2022	SELL	$4.82 - $7.45 $55,463 - $85,727	-11,507 Reduced 89.19%	1,394 $8,000
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.45 $55,463 - $85,727	-11,507 Reduced 89.19%	1,394 $8,000
Q1 2022 Oct 27, 2022	BUY	$5.6 - $8.22 $64,439 - $94,587	11,507 Added 825.47%	12,901 $92,000
Q1 2022 May 13, 2022	SELL	$5.6 - $8.22 $215,264 - $315,976	-38,440 Reduced 74.87%	12,901 $92,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $11.04 $24,266 - $37,679	3,413 Added 7.12%	51,341 $410,000
Q3 2021 Nov 15, 2021	BUY	$10.53 - $14.93 $504,681 - $715,565	47,928 New	47,928 $535,000

Others Institutions Holding LTRN

# of Institutions

Shares Held

1.26M

Call Options Held

42.8K

Put Options Held

5.6K

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $40.9M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account